Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“First Generics” Will Get Expedited ANDA Reviews Under New FDA Policy

Executive Summary

FDA's "First Generics" policy sets a priority review goal of six months for ANDAs for which there is no marketed generic equivalent

You may also be interested in...



ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office

CDER staff manual outlines seven categories of submissions that can qualify for expedited review, including some ANDAs with patent certifications and supplements that have the potential to create an “extraordinary hardship” for a sponsor if not addressed quickly.

GIVE Generics A Break: FDA Review Plan Draws Grumbles From Industry

FDA's announcement about its new review procedures for generic drugs may well be tailored to have more impact on congressional appropriations committees than on the ANDAs themselves

GIVE Generics A Break: FDA Review Plan Draws Grumbles From Industry

FDA's announcement about its new review procedures for generic drugs may well be tailored to have more impact on congressional appropriations committees than on the ANDAs themselves

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047678

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel